The presentation of promising clinical activity and a tolerable safety profile for alisertib in a Phase II study at a major conference like ASCO is likely to positively impact Puma Biotechnology's stock price in the short term. Investors often react favorably to positive clinical trial results, especially in the biopharmaceutical sector.